GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Shares Outstanding (EOP)

Cannara Biotech (TSXV:LOVE) Shares Outstanding (EOP) : 90.02 Mil (As of Feb. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cannara Biotech's shares outstanding for the quarter that ended in Feb. 2024 was 90.02 Mil.

Cannara Biotech's quarterly shares outstanding declined from Nov. 2023 (90.02 Mil) to Feb. 2024 (90.02 Mil). It means Cannara Biotech bought back shares from Nov. 2023 to Feb. 2024 .

Cannara Biotech's annual shares outstanding increased from Aug. 2022 (87.70 Mil) to Aug. 2023 (90.31 Mil). It means Cannara Biotech issued new shares from Aug. 2022 to Aug. 2023 .


Cannara Biotech Shares Outstanding (EOP) Historical Data

The historical data trend for Cannara Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Shares Outstanding (EOP) Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 70.68 73.77 87.65 87.70 90.31

Cannara Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.67 90.51 90.31 90.02 90.02

Competitive Comparison of Cannara Biotech's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Shares Outstanding (EOP) falls into.



Cannara Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Cannara Biotech  (TSXV:LOVE) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cannara Biotech Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech (TSXV:LOVE) Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director